ERBB2 and breast cancer: In the current study, we have estimated the RS in a heterogenous Indian institutional cohort of 55 HR positive and HER2/neu negative BC patients, irrespective of node status and compared the estimated score with the open source available updated web-based MEs, Predict and CTS5 Calculator to determine the relevance and possible correlation.